|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
PL3102605T3
(pl)
|
2014-02-04 |
2019-06-28 |
Pfizer Inc. |
Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
|
|
JP6447933B2
(ja)
|
2014-02-21 |
2019-01-09 |
アイビーシー ファーマスーティカルズ，インコーポレイテッド |
Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
|
|
ES2913205T3
(es)
|
2014-05-13 |
2022-06-01 |
Bioatla Inc |
Proteínas biológicas activas condicionalmente
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
EP4141032B1
(en)
|
2014-11-20 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
EP3865139B1
(en)
|
2015-02-18 |
2023-05-03 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
WO2016170541A1
(en)
|
2015-04-21 |
2016-10-27 |
Enlivex Therapeutics Ltd. |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
RU2714233C2
(ru)
|
2015-02-26 |
2020-02-13 |
Мерк Патент Гмбх |
Ингибиторы pd-1 / pd-l1 для лечения рака
|
|
CN114920848B
(zh)
*
|
2015-05-13 |
2024-10-11 |
埃博灵克斯股份有限公司 |
基于cd3反应性的t细胞募集多肽
|
|
AU2016274989A1
(en)
*
|
2015-06-12 |
2017-11-02 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
|
JP2018516950A
(ja)
*
|
2015-06-12 |
2018-06-28 |
イミュンジーン, インコーポレイテッドImmunGene, Inc. |
がん治療のための集中インターフェロン免疫療法
|
|
MY193229A
(en)
|
2015-06-16 |
2022-09-26 |
Merck Patent GmbH |
Pd-l1 antagonist combination treatments
|
|
JP2018519832A
(ja)
*
|
2015-06-30 |
2018-07-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
多重特異的結合タンパク質
|
|
TWI746449B
(zh)
*
|
2015-07-20 |
2021-11-21 |
美商Ａｉ治療公司 |
使用阿吡莫德治療癌症之方法
|
|
US11045547B2
(en)
|
2015-12-16 |
2021-06-29 |
Merck Sharp & Dohme Corp. |
Anti-LAG3 antibodies and antigen-binding fragments
|
|
EP3400218A4
(en)
*
|
2016-01-08 |
2019-09-18 |
Euclises Pharmaceuticals, Inc. |
COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
CN109069539A
(zh)
|
2016-02-18 |
2018-12-21 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的联合免疫疗法和细胞因子控制疗法
|
|
KR20180133442A
(ko)
*
|
2016-04-13 |
2018-12-14 |
비비아 바이오테크 에스.엘. |
생체외 bite 활성화된 t 세포
|
|
US20190282679A1
(en)
|
2016-04-18 |
2019-09-19 |
Rima McLeod |
Toxoplasma gondii vaccines and their use
|
|
AU2017257254B2
(en)
*
|
2016-04-27 |
2022-02-24 |
Immunomedics, Inc. |
Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
|
WO2017189906A1
(en)
*
|
2016-04-27 |
2017-11-02 |
Mira Dx, Inc. |
Immune-based treatment of kras-variant cancer patients
|
|
CN109195992A
(zh)
*
|
2016-04-29 |
2019-01-11 |
本康生物制药（深圳）有限公司 |
多特异性结合偶联物、相关的药物组合物及应用
|
|
AU2017261353A1
(en)
*
|
2016-05-05 |
2018-11-08 |
Nantomics, Llc |
Checkpoint failure and methods therefor
|
|
WO2017214575A1
(en)
*
|
2016-06-10 |
2017-12-14 |
Io Therapeutics, Inc. |
Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
|
|
CN105943510A
(zh)
*
|
2016-06-13 |
2016-09-21 |
佛山市腾瑞医药科技有限公司 |
一种艾代拉利司制剂及其应用
|
|
EP4101447A1
(en)
|
2016-06-30 |
2022-12-14 |
Nant Holdings IP, LLC |
Nant cancer vaccine
|
|
WO2018028449A1
(en)
*
|
2016-08-08 |
2018-02-15 |
Beigene, Ltd. |
Method for predicting efficacy of immune checkpoint inhibitors in cancer patients
|
|
ES2981272T3
(es)
|
2016-09-23 |
2024-10-08 |
Merus Nv |
Moléculas de unión que modulan una actividad biológica expresada por una célula
|
|
US12188935B2
(en)
|
2016-09-30 |
2025-01-07 |
Centre National De La Recherche Scientifique |
Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
|
|
EP3904880A1
(fr)
*
|
2016-09-30 |
2021-11-03 |
Centre national de la recherche scientifique |
Marqueurs membranaires
|
|
KR20190062515A
(ko)
|
2016-10-06 |
2019-06-05 |
화이자 인코포레이티드 |
암의 치료를 위한 아벨루맙의 투약 용법
|
|
JP6948685B2
(ja)
*
|
2016-11-04 |
2021-10-13 |
国立大学法人金沢大学 |
抗癌作用増強剤及び癌治療支援方法
|
|
CA3041375A1
(en)
*
|
2016-11-04 |
2018-05-11 |
Vaximm Ag |
Wt1 targeting dna vaccine for combination therapy
|
|
EP3541838A1
(en)
*
|
2016-11-16 |
2019-09-25 |
Eli Lilly and Company |
Therapy for metatastic colorectal cancer using anti-vegfr-2 and anti-vegf-d antibodies
|
|
CN110573172A
(zh)
|
2017-02-06 |
2019-12-13 |
奥里尼斯生物科学有限公司 |
靶向的工程化干扰素及其用途
|
|
JP2020508323A
(ja)
*
|
2017-02-23 |
2020-03-19 |
ラクテン メディカル インコーポレイテッド |
光免疫療法のための治療用組成物および関連する方法
|
|
WO2018178047A1
(en)
*
|
2017-03-29 |
2018-10-04 |
Glycotope Gmbh |
Multispecific antibody constructs binding to muc1 and cd3
|
|
CN110505883A
(zh)
*
|
2017-04-13 |
2019-11-26 |
豪夫迈·罗氏有限公司 |
供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
|
|
WO2019014468A1
(en)
|
2017-07-13 |
2019-01-17 |
Io Therapeutics, Inc. |
RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY
|
|
US10363272B2
(en)
|
2017-08-31 |
2019-07-30 |
Io Therapeutics, Inc. |
RAR selective agonists in combination with immune modulators for cancer immunotherapy
|
|
CN111491665B
(zh)
*
|
2017-09-26 |
2024-08-06 |
中外制药株式会社 |
药物组合物
|
|
CN109954131B
(zh)
*
|
2017-12-14 |
2023-05-02 |
深圳市中科艾深医药有限公司 |
一种肿瘤坏死因子相关凋亡诱导配体拮抗剂作为脓毒血症治疗药物的应用
|
|
US20190184028A1
(en)
*
|
2017-12-14 |
2019-06-20 |
Janssen Biotech, Inc. |
Targeting with firbronectin type iii like domain molecules
|
|
AU2019221544B2
(en)
*
|
2018-02-13 |
2025-07-10 |
Precision Biologics, Inc. |
Methods and compositions for targeting Treg cells
|
|
KR102373502B1
(ko)
|
2018-05-14 |
2022-03-11 |
주식회사 금호에이치티 |
골수유래억제세포 관련 질환의 예방 및 치료 용도
|
|
EP3569617A1
(en)
*
|
2018-05-18 |
2019-11-20 |
Trion Research GmbH |
Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
|
|
EP3802595A1
(en)
*
|
2018-06-07 |
2021-04-14 |
OncoOne Research & Development GmbH |
Anti-oxmif/anti-cd3 antibody for cancer treatment
|
|
JP7541930B2
(ja)
*
|
2018-06-29 |
2024-08-29 |
ジーオー セラピューティクス，インコーポレイテッド |
抗グリコｍｕｃ１抗体およびその使用
|
|
BR112021001992A2
(pt)
*
|
2018-08-02 |
2021-05-04 |
The Board Of Regents Of The University Of Texas System |
efeito adjuvante do agonista tlr1/2 diprovocim sinergiza com anticorpos inibidores de checkpoint para eliminar doença
|
|
KR102817790B1
(ko)
*
|
2018-08-29 |
2025-06-05 |
케모센트릭스, 인크. |
C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법
|
|
EP3860715A1
(en)
*
|
2018-10-04 |
2021-08-11 |
Genmab Holding B.V. |
Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
|
|
KR102297440B1
(ko)
*
|
2018-10-05 |
2021-09-02 |
알엔에이진(주) |
표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도
|
|
WO2020092839A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
EP3873540A4
(en)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
EP3897844B1
(en)
*
|
2018-12-19 |
2023-11-15 |
Deutsches Krebsforschungszentrum |
Pharmaceutical combination of anti ceacam6 and tim3 antibodies
|
|
CN110846279B
(zh)
*
|
2018-12-27 |
2023-06-16 |
重庆医药高等专科学校附属第一医院 |
人套细胞淋巴瘤细胞株及其建立方法和应用
|
|
EP3914621A1
(en)
*
|
2019-01-21 |
2021-12-01 |
Singapore Health Services Pte. Ltd. |
Treatment of hepatotoxicity
|
|
TWI899079B
(zh)
*
|
2019-05-23 |
2025-10-01 |
美商維洛斯生物公司 |
抗ror1/抗cd3雙特異性結合分子
|
|
KR20210021861A
(ko)
*
|
2019-08-19 |
2021-03-02 |
(주)제노팜 |
사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법
|
|
EP4061487A4
(en)
*
|
2019-11-19 |
2023-12-20 |
Rootpath Genomics, Inc. |
COMPOSITIONS AND METHODS FOR IDENTIFYING T CELL RECEPTOR
|
|
US20230242655A1
(en)
|
2019-12-03 |
2023-08-03 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins and uses thereof
|
|
EP4125946A4
(en)
*
|
2020-03-27 |
2024-04-24 |
Board of Regents, The University of Texas System |
MONOCLONAL ANTIBODIES TARGETING HSP70 AND THEIR THERAPEUTIC USES
|
|
US20230241237A1
(en)
*
|
2020-04-16 |
2023-08-03 |
Emory University |
Immune Cell Redirecting Compositions and Therapeutic Uses Thereof
|
|
CN111705013B
(zh)
*
|
2020-06-02 |
2021-12-07 |
华中农业大学 |
一种牛支原体Mbov_0570基因突变株及其应用
|
|
AU2021292488A1
(en)
*
|
2020-06-15 |
2023-02-02 |
Monopar Therapeutics, Inc. |
Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (uPAR) for treatment of severe COVID-19 disease
|
|
CN111850002B
(zh)
*
|
2020-06-22 |
2022-04-19 |
华中农业大学 |
牛支原体分泌蛋白MbovP570的应用
|
|
GB202011993D0
(en)
|
2020-07-31 |
2020-09-16 |
Adc Therapeutics Sa |
ANTI-IL 13Ra2 antibodies
|
|
WO2022046658A1
(en)
*
|
2020-08-24 |
2022-03-03 |
Janux Therapeutics, Inc. |
Antibodies targeting trop2 and cd3 and uses thereof
|
|
IL300835A
(en)
*
|
2020-09-02 |
2023-04-01 |
Genmab As |
Antibody therapy
|
|
EP4247412A4
(en)
*
|
2020-11-18 |
2024-10-23 |
University of Florida Research Foundation, Inc. |
Materials and methods for sensitizing tumors to immune response
|
|
JP2022157223A
(ja)
*
|
2021-03-31 |
2022-10-14 |
国立大学法人神戸大学 |
抗ガン剤効果増強剤
|
|
TWI910028B
(zh)
|
2021-06-11 |
2025-12-21 |
美商基利科學股份有限公司 |
Mcl-1抑制劑與抗癌劑之組合
|
|
US11931424B2
(en)
|
2021-06-11 |
2024-03-19 |
Gilead Sciences, Inc. |
Combination MCL-1 inhibitors with anti-body drug conjugates
|
|
CN115671253B
(zh)
*
|
2021-07-30 |
2024-02-27 |
河北菲尼斯生物技术有限公司 |
Se-dr亲和肽在制备治疗风湿疾病的药物中的用途
|
|
WO2023056240A2
(en)
|
2021-09-28 |
2023-04-06 |
Frontaim Biomedicines, Inc. |
Multiple formats of molecular complexes
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
US12122764B2
(en)
|
2021-12-22 |
2024-10-22 |
Gilead Sciences, Inc. |
IKAROS zinc finger family degraders and uses thereof
|
|
KR20240123836A
(ko)
|
2021-12-22 |
2024-08-14 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
CN114209652B
(zh)
*
|
2021-12-29 |
2022-08-09 |
中山大学附属第一医院 |
一种微环境nk细胞免疫调控递送系统及其制备方法和应用
|
|
CN114300089B
(zh)
*
|
2022-01-04 |
2024-09-03 |
哈尔滨医科大学 |
一种中晚期结直肠癌治疗方案决策算法
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
US12365743B2
(en)
|
2022-02-23 |
2025-07-22 |
Xencor, Inc. |
Anti-CD28 x anti-PSMA antibodies
|
|
WO2023164640A1
(en)
*
|
2022-02-24 |
2023-08-31 |
Xencor, Inc. |
Anti-cd28 x anti-trop2 antibodies
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CA3256048A1
(en)
|
2022-04-13 |
2023-10-19 |
Arcus Biosciences, Inc. |
POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING A TUMOR ANTIGEN
|
|
JP2025512384A
(ja)
|
2022-04-13 |
2025-04-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｔｒｏｐ－２発現がんを治療するための併用療法
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
KR20250028371A
(ko)
|
2022-07-01 |
2025-02-28 |
길리애드 사이언시즈, 인코포레이티드 |
Cd73 화합물
|
|
TW202413405A
(zh)
*
|
2022-07-13 |
2024-04-01 |
美商翰森生物有限責任公司 |
抗體、其抗原結合片段及其藥物用途
|
|
WO2024097812A1
(en)
|
2022-11-04 |
2024-05-10 |
Gilead Sciences, Inc. |
Therapy for treating bladder cancer
|
|
CN115975026B
(zh)
*
|
2022-11-15 |
2024-06-25 |
青海大学 |
一种抗多房棘球蚴原头节的纳米抗体、重组菌及其应用
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CR20250446A
(es)
|
2023-04-21 |
2025-12-02 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
CN121620513A
(zh)
|
2023-07-26 |
2026-03-06 |
吉利德科学公司 |
Parp7抑制剂
|
|
WO2025027090A1
(en)
*
|
2023-07-31 |
2025-02-06 |
Danmarks Tekniske Universitet |
Inhibitors of cell envelope proteinases from lactic acid bacteria
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
CN116874606B
(zh)
*
|
2023-09-08 |
2023-11-24 |
益科思特(北京)医药科技发展有限公司 |
一种靶向trop2和cd3的双特异性抗体及其制备方法与应用
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025184896A1
(zh)
*
|
2024-03-08 |
2025-09-12 |
四川大学华西医院 |
增强免疫检查点抑制剂抗肿瘤疗效的方法和药物及其应用
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN120518757B
(zh)
*
|
2025-07-23 |
2025-09-23 |
中国人民解放军军事科学院军事医学研究院 |
一种聚乙二醇化多价抗西尼罗病毒单链抗体
|
|
CN121293363B
(zh)
*
|
2025-12-09 |
2026-04-21 |
上海玄言生物科技有限公司 |
一种靶向cd14和cd3的双功能t细胞衔接器及其应用
|